NPJ Vaccines最新文献_第5页

Development of a multi-epitope mRNA vaccine targeting tumor-associated antigens for esophageal squamous cell carcinoma. 针对食管鳞状细胞癌肿瘤相关抗原的多表位mRNA疫苗的研制

IF 7.2 1区医学

NPJ Vaccines Pub Date : 2026-06-19 DOI: 10.1038/s41541-026-01503-y

Henghui Zhang, Hao Liang, Tingting Dai, Ning Shen, Chenlu Liu, Yang Zhou, Zhenhua Wei, Zhongqiu Wu, Pengfei Yu, Quan Zhang, Xiaona Zhang, Jinxuan Yu, Xuefeng Ji, Airong Yang, Cuiping An, Ying Han, Xi Jiao, Lu Qian, Zhihao Lu

{"title":"Development of a multi-epitope mRNA vaccine targeting tumor-associated antigens for esophageal squamous cell carcinoma.","authors":"Henghui Zhang, Hao Liang, Tingting Dai, Ning Shen, Chenlu Liu, Yang Zhou, Zhenhua Wei, Zhongqiu Wu, Pengfei Yu, Quan Zhang, Xiaona Zhang, Jinxuan Yu, Xuefeng Ji, Airong Yang, Cuiping An, Ying Han, Xi Jiao, Lu Qian, Zhihao Lu","doi":"10.1038/s41541-026-01503-y","DOIUrl":"10.1038/s41541-026-01503-y","url":null,"abstract":"Esophageal squamous cell carcinoma (ESCC) has limited treatment options post-immune checkpoint inhibitor (ICI) resistance. We developed IPM514, a universal multi-epitope mRNA lipid nanoparticle (LNP) vaccine targeting tumor-associated antigens identified via transcriptomic analysis of TCGA/GTEx datasets and validated in 132 ESCC patients. IPM514 contains 15 fragments from 9 antigens, covering most patients and over half of HLA subtypes. Peripheral blood mononuclear cells (PBMCs) from healthy donors and ESCC patients stimulated with IPM514 effectively expanded specific T cells that exhibited significant cytotoxic activity against ESCC and other squamous cell carcinomas with similar antigen profiles. In HLA-transgenic mouse models, IPM514 suppressed tumor growth, extended survival, and provided durable protection. Importantly, combination therapy with PD-1 blockade augmented antitumor efficacy by promoting immune cell infiltration, upregulating antigen presentation pathways, and reprogramming the tumor microenvironment toward an anti-tumorigenic state. These results demonstrate IPM514 represents a promising novel mRNA vaccine strategy for improving ESCC immunotherapy.","PeriodicalId":19335,"journal":{"name":"NPJ Vaccines","volume":" ","pages":""},"PeriodicalIF":7.2,"publicationDate":"2026-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13639008/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148278135","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Evaluating large language models on multilingual vaccine knowledge: a benchmark study. 评估多语言疫苗知识的大型语言模型：一项基准研究。

IF 7.2 1区医学

NPJ Vaccines Pub Date : 2026-06-10 DOI: 10.1038/s41541-026-01500-1

Siyuan Chen, Lily Wass, Zhengdong Wu, Lucas Garay, José Vizoso, Kathy Leung, Joseph Wu, Leesa Lin

{"title":"Evaluating large language models on multilingual vaccine knowledge: a benchmark study.","authors":"Siyuan Chen, Lily Wass, Zhengdong Wu, Lucas Garay, José Vizoso, Kathy Leung, Joseph Wu, Leesa Lin","doi":"10.1038/s41541-026-01500-1","DOIUrl":"10.1038/s41541-026-01500-1","url":null,"abstract":"Large language models (LLMs) are increasingly used by clinicians and the public for vaccine information, yet their factual accuracy across languages and vaccine domains remains insufficiently characterized. We evaluated 13 LLMs using VaxEval, a multilingual vaccine-knowledge benchmark of 1886 vaccine-related multiple-choice questions spanning 14 vaccines in English (71%), Spanish (13%), and Chinese (16%). All items underwent quality control, with reference answers verified against authoritative guidance and peer-reviewed sources. Model performance was evaluated under zero-shot, few-shot, and chain-of-thought (CoT) prompting, with exact-match accuracy defined as selecting the pre-specified reference option. We used mixed-effect logistic regression to estimate associations between model group (newer flagship models vs earlier models), prompting strategy, language, and vaccine type, and answer correctness. Mean accuracy across models was 86.0% in English, 83.7% in Spanish, and 80.0% in Chinese. Flagship models had higher odds of correctness than earlier versions (OR 1.57; 95% CI 1.50-1.65; P < .001). Few-shot prompting was associated with higher correctness (OR 1.17; P < .001), whereas CoT prompting was associated with lower correctness (OR 0.79; P < .001). Performance varied by vaccine type and question category, underscoring the need for rigorous evaluation, structured guardrails, and targeted refinement before using LLMs for vaccine communication.","PeriodicalId":19335,"journal":{"name":"NPJ Vaccines","volume":" ","pages":""},"PeriodicalIF":7.2,"publicationDate":"2026-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13642938/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148218557","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pre-clinical efficacy of a candidate outer membrane vesicle gonococcal vaccine in comparison with 4CMenB. 一种候选外膜囊泡淋球菌疫苗与4CMenB的临床前疗效比较

IF 7.2 1区医学

NPJ Vaccines Pub Date : 2026-06-08 DOI: 10.1038/s41541-026-01491-z

Paula Freixeiro, Lisa A Lewis, Leonor Sánchez-Busó, Magnus Unemo, Sunita Gulati, Aline Linder, Jukka Corander, Odile B Harrison, Christina Dold, Simon Harris, Christine S Rollier, Sanjay Ram, Calman A MacLennan

{"title":"Pre-clinical efficacy of a candidate outer membrane vesicle gonococcal vaccine in comparison with 4CMenB.","authors":"Paula Freixeiro, Lisa A Lewis, Leonor Sánchez-Busó, Magnus Unemo, Sunita Gulati, Aline Linder, Jukka Corander, Odile B Harrison, Christina Dold, Simon Harris, Christine S Rollier, Sanjay Ram, Calman A MacLennan","doi":"10.1038/s41541-026-01491-z","DOIUrl":"10.1038/s41541-026-01491-z","url":null,"abstract":"Neisseria gonorrhoeae causes 82 million global cases of gonorrhoea annually. Multidrug-resistant gonococci threaten to make gonorrhoea untreatable. Meningococcal vaccines MeNZB and 4CMenB (Bexsero), containing Neisseria meningitidis group B detergent-extracted outer membrane vesicles (dOMV), cross-protect against gonorrhoea with 31-59% effectiveness. We hypothesised that gonococcal OMV-based vaccines would have greater efficacy against gonorrhoea than meningococcal vaccines. We developed native OMV (nOMV) candidate Neisseria vaccines from gonococcal strains GC_0817560 and FA1090, and meningococcal B strain NZ98/254. lpxL1 and rmp genes were deleted to reduce reactogenicity and minimise induction of unprotective or blocking antibodies. nOMV were characterised and formulated with aluminium hydroxide. Deletion of lpxL1 markedly reduced nOMV-induced IL-6 release from peripheral blood mononuclear cells. nOMV derived from GC_0817560lpxL1-rmp- and FA1090lpxL1-rmp- induced greater quantities of gonococcal-specific serum IgG and accelerated clearance of FA1090 from oestradiol-treated BALB/c mice significantly faster than 4CMenB and NZ98/254lpxL1-rmp- nOMV (P < 0.0001). Gonococcal nOMV-based vaccines represent promising candidates for further development.","PeriodicalId":19335,"journal":{"name":"NPJ Vaccines","volume":" ","pages":""},"PeriodicalIF":7.2,"publicationDate":"2026-06-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13315605/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148205596","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Genetically diverse CC and DO mouse models enable comprehensive assessments of novel tuberculosis vaccines. 基因多样化的CC和DO小鼠模型能够对新型结核病疫苗进行全面评估。

IF 7.2 1区医学

NPJ Vaccines Pub Date : 2026-06-05 DOI: 10.1038/s41541-026-01498-6

Rocky Lai, Sherry L Kurtz, Victoria Gould, Anthony Tran, Sam Afkhami, Roland Brosch, Cecilia S Lindestam Arlehamn, Zhou Xing, Karen L Elkins, Samuel M Behar

{"title":"Genetically diverse CC and DO mouse models enable comprehensive assessments of novel tuberculosis vaccines.","authors":"Rocky Lai, Sherry L Kurtz, Victoria Gould, Anthony Tran, Sam Afkhami, Roland Brosch, Cecilia S Lindestam Arlehamn, Zhou Xing, Karen L Elkins, Samuel M Behar","doi":"10.1038/s41541-026-01498-6","DOIUrl":"10.1038/s41541-026-01498-6","url":null,"abstract":"Development of a new vaccine for tuberculosis (TB) to replace the BCG vaccine has been hampered by the lack of a preclinical vaccine model that accurately reflects the genetic heterogeneity of the human population. We previously tested both Collaborative Cross (CC) and Diversity Outbred (DO) mice, which collectively reflect the genetic diversity of an outbred population, as models for preclinical vaccine testing. Using both CC and DO mice, we compared the ability of two different strategies to enhance BCG-mediated protection against Mycobacterium tuberculosis (Mtb). BCG::ESX-1Mmar is genetically modified to express the esx-1 region of Mycobacterium marinum. In contrast, the BCG/ChAd:TB strategy relies on boosting BCG-induced immunity using a chimp adenoviral vectored vaccine expressing the mycobacterial antigens Ag85A, TB10.4, and RpfB administered by the intranasal route. Both BCG::ESX-1Mmar and BCG/ChAd:TB vaccination strategies significantly protect mouse strains that were not well protected by BCG. Although both vaccination strategies were associated with reduced bacterial growth in CC and DO mice, bacterial control did not correlate with survival. Both BCG::ESX-1Mmar and BCG/ChAd:TB induced immune signatures after Mtb challenge in the tested CC strains that were previously associated with protection in traditional inbred mouse strains. Our findings established the use of both CC and DO mice as robust platforms that incorporate host genetic diversity for the preclinical evaluation of TB vaccines.","PeriodicalId":19335,"journal":{"name":"NPJ Vaccines","volume":" ","pages":""},"PeriodicalIF":7.2,"publicationDate":"2026-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13558714/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148176469","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Response to vaccination and immune status after intrauterine exposure to immunomodulating drugs for maternal IBD. 孕妇在宫内暴露于免疫调节药物后对疫苗接种和免疫状态的反应。

IF 7.2 1区医学

NPJ Vaccines Pub Date : 2026-06-05 DOI: 10.1038/s41541-026-01499-5

Jantien W Wieringa, Mirjam J Esser, Matthijs D Kruizinga, Gerco den Hartog, Lyanne W Rövekamp, Esther G J Rijntjes-Jacobs, Herbert M van Wering, Gerdien A Tramper-Stranders, Willem A Dik, Marjan Kuijer, Nynke Y Rots, Gertjan J A Driessen

{"title":"Response to vaccination and immune status after intrauterine exposure to immunomodulating drugs for maternal IBD.","authors":"Jantien W Wieringa, Mirjam J Esser, Matthijs D Kruizinga, Gerco den Hartog, Lyanne W Rövekamp, Esther G J Rijntjes-Jacobs, Herbert M van Wering, Gerdien A Tramper-Stranders, Willem A Dik, Marjan Kuijer, Nynke Y Rots, Gertjan J A Driessen","doi":"10.1038/s41541-026-01499-5","DOIUrl":"10.1038/s41541-026-01499-5","url":null,"abstract":"Guidelines on inflammatory bowel disease (IBD) recommend continuing immunomodulating drugs during pregnancy, but their effects on the infant immune system remain uncertain. In this observational study, infants exposed to maternal IBD medication were vaccinated according to the Dutch National Immunization Program. We measured vaccine-specific IgG at 6 and 12 months and leukocytes, lymphocyte subsets, immunoglobulins, and infections at 2, 6, and 12 months of age. Vaccine responses and lymphocyte subsets were compared with historical cohorts and other outcomes with age-specific reference ranges. Vaccine responses following a 3 + 1 vaccination schedule were comparable to or higher than controls following a 2 + 1 schedule for all vaccine components, except filamentous haemagglutinin (FHA) and pneumococcal serotype 19 F. Neutropenia occurred more frequently than expected from reference values, but was self-limiting in all cases. The proportion of infants with T- or total B-cell lymphopenia did not differ from healthy controls. At 6 months, 9.8% of infants had mildly reduced total IgG concentrations, and low IgA was observed in 28.1%, 41.3%, and 15.4% at 2, 6, and 12 months, respectively; significantly more than expected based on reference values. The observed infection rate was similar to that reported in the literature. These findings may help develop clinical follow-up guidelines.","PeriodicalId":19335,"journal":{"name":"NPJ Vaccines","volume":" ","pages":""},"PeriodicalIF":7.2,"publicationDate":"2026-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13558638/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148176459","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Population-level impact of quadrivalent HPV vaccination in Brazil: a repeated cross-sectional study. 巴西四价HPV疫苗接种对人群水平的影响：一项重复的横断面研究。

IF 7.2 1区医学

NPJ Vaccines Pub Date : 2026-06-04 DOI: 10.1038/s41541-026-01495-9

Eliana Marcia Wendland, Rafael Steffens Martins, Natália Luiza Kops, Gustavo Eidt, Thayane Martins Dornelles, Ana Goretti Kalume Maranhão, Pâmela Cristina Gaspar, Draurio Barreira Cravo Neto, Luisa Villa, Adele Schwartz Benzaken

{"title":"Population-level impact of quadrivalent HPV vaccination in Brazil: a repeated cross-sectional study.","authors":"Eliana Marcia Wendland, Rafael Steffens Martins, Natália Luiza Kops, Gustavo Eidt, Thayane Martins Dornelles, Ana Goretti Kalume Maranhão, Pâmela Cristina Gaspar, Draurio Barreira Cravo Neto, Luisa Villa, Adele Schwartz Benzaken","doi":"10.1038/s41541-026-01495-9","DOIUrl":"10.1038/s41541-026-01495-9","url":null,"abstract":"Human papillomavirus vaccination is central to cervical cancer elimination, yet population-level evidence from middle-income countries remains limited. We evaluated the impact of quadrivalent HPV vaccination in Brazil using data from two repeated population-based cross-sectional surveys conducted in 2016-2017 and 2020-2023 among sexually active individuals aged 16-25 years. Genital samples were tested for HPV genotyping and survey-weighted Poisson-regression models adjusted for sociodemographic and behavioral factors were used to compare prevalences between periods. Among 11,794 women and 4932 men, the prevalence of vaccine-type HPV declined from 15.64% (14.23-17.17) to 5.92% (5.23-6.70) among women and 13.81% (11.15-16.99) to 10.39% (8.35-12.85) among men. Adjusted analyses showed an 81% reduction among vaccinated women (PR0.19; 0.14-0.27) and a 33% reduction among unvaccinated women (PR0.67; 0.55-0.81), suggesting both direct and indirect effects. Reductions were significant only among women aged 16-23, the group with higher coverage. Among men, lower prevalence of vaccine-type HPV was observed only among vaccinated individuals (PR0.39; 0.18-0.86). The overall HPV prevalence increased modestly between the two surveys. No differences in prevalence reduction were observed according to the number of vaccine doses. These findings demonstrated the impact of HPV vaccination in Brazil and highlight the importance of maintaining high vaccination coverage and continued surveillance.","PeriodicalId":19335,"journal":{"name":"NPJ Vaccines","volume":" ","pages":""},"PeriodicalIF":7.2,"publicationDate":"2026-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13550542/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148163698","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Chitosan nanoparticles for mucosal and needle-free vaccination. 壳聚糖纳米颗粒用于粘膜和无针疫苗接种。

IF 7.2 1区医学

NPJ Vaccines Pub Date : 2026-06-03 DOI: 10.1038/s41541-026-01496-8

Changchun Chen, Cheng Zhang, Shanyuan Zhu, Shinuo Cao

引用次数: 0

Schistosomiasis vaccine SchistoShield® induces functional immune memory responses in US and African populations. SchistoShield®在美国和非洲人群中诱导功能性免疫记忆反应。

IF 7.2 1区医学

NPJ Vaccines Pub Date : 2026-06-02 DOI: 10.1038/s41541-026-01501-0

Mumtaz Y Balkhi, Aravindan Kalyanasundaram, Aryandra Arya, Desalegn W Kifle, Mallory Mckinnon, Dinesh Krishnappa, Harshvardhan Shrivastava, Mohamadou Siribie, Asma Aziz, Hyonjin Jeon, Tanyada Yongchaitrakul, Birkneh T Tadesse, Njariharinjakamampionona Rakotozandrindrainy, Ravomialisoa Razafimanantsoa, Henry Bere Noellie, Nebié Issa Ouedraogo, Amidou Diarra, Sean A Gray, Rhea N Coler, Jinhee Lee, Raphaël Rakotozandrindrainy, Sodiomon B Sirima, Lisa A Jackson, Florian Marks, Darrick Carter, Afzal A Siddiqui

{"title":"Schistosomiasis vaccine SchistoShield® induces functional immune memory responses in US and African populations.","authors":"Mumtaz Y Balkhi, Aravindan Kalyanasundaram, Aryandra Arya, Desalegn W Kifle, Mallory Mckinnon, Dinesh Krishnappa, Harshvardhan Shrivastava, Mohamadou Siribie, Asma Aziz, Hyonjin Jeon, Tanyada Yongchaitrakul, Birkneh T Tadesse, Njariharinjakamampionona Rakotozandrindrainy, Ravomialisoa Razafimanantsoa, Henry Bere Noellie, Nebié Issa Ouedraogo, Amidou Diarra, Sean A Gray, Rhea N Coler, Jinhee Lee, Raphaël Rakotozandrindrainy, Sodiomon B Sirima, Lisa A Jackson, Florian Marks, Darrick Carter, Afzal A Siddiqui","doi":"10.1038/s41541-026-01501-0","DOIUrl":"10.1038/s41541-026-01501-0","url":null,"abstract":"Helminth parasites of the genus Schistosoma cause 290,000 deaths annually, mostly in tropical and subtropical regions. An estimated 250 million people are currently chronically infected with Schistosoma parasites, imposing a risk of new and recurrent infections in an additional 800 million people. SchistoShield® (Sm-p80 + GLA-SE) is a leading vaccine candidate for schistosomiasis that has successfully completed Phase 1 (USA) and Phase 1b (Africa) safety and immunogenicity clinical trials. Using Peripheral Blood Mononuclear Cells (PBMCs) obtained from intercontinental Phase 1 and Phase 1b trial participants, adaptive immune effector and memory responses to SchistoShield® were investigated. Functional recall responses were measured in vitro using Sm-p80 vaccine antigen. Results clearly demonstrate that the vaccine induced pronounced effector and memory T-cell responses. Upon recall with Sm-p80 antigen, cytokines including IFN-γ, TNF-α, IL-17A, IL-9, and granzyme B were produced, indicating the generation of functionally heterogeneous CD4 T-helper and cytotoxic lymphocyte responses. Consistent with T-helper responses that promote humoral immunity, Sm-p80 antigen-specific antibody-secreting plasmablasts were detected in vaccinated volunteers who were tracked longitudinally. Taken together, the SchistoShield® vaccine induced robust cell-mediated effector and memory responses, hallmarks of a potentially efficacious vaccine against schistosome/helminth parasites.","PeriodicalId":19335,"journal":{"name":"NPJ Vaccines","volume":" ","pages":""},"PeriodicalIF":7.2,"publicationDate":"2026-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13526879/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148150471","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Author Correction: Production of an immunogenic trivalent poliovirus virus-like particle vaccine candidate in yeast using controlled fermentation. 作者更正：在酵母中使用控制发酵生产免疫原性三价脊髓灰质炎病毒样颗粒疫苗。

IF 6.5 1区医学

NPJ Vaccines Pub Date : 2026-05-29 DOI: 10.1038/s41541-026-01470-4

Lee Sherry, Keith Grehan, Mohammad W Bahar, Jessica J Swanson, Helen Fox, Sue Matthews, Sarah Carlyle, Ling Qin, Claudine Porta, Steven Wilkinson, Suzanne Robb, Naomi Clark, John Liddell, Elizabeth E Fry, David I Stuart, Andrew J Macadam, David J Rowlands, Nicola J Stonehouse

引用次数: 0

MVA-BN monkeypox vaccine safety in a clinical trial in the Democratic Republic of the Congo. MVA-BN猴痘疫苗在刚果民主共和国临床试验中的安全性。

IF 7.2 1区医学

NPJ Vaccines Pub Date : 2026-05-28 DOI: 10.1038/s41541-026-01490-0

Nsengi Ntamabyaliro, Tyler Bonnett, Gail Potter, Emily Yox, Laurens Liesenborghs, Olivier Tshiani Mbaya, Veronique Nussenblatt, Tarcisse Kapene Kilara, Aline Biongo Engo, Emmanuella Muhima, Percy Velela, Laetitia Itunime, Jean-Luc Biampata, Placide Mbala, Mariano Lusakibanza, Michael Kombozi Basika, Gaston Tona, Susan Vogel, H Clifford Lane, Lori E Dodd, Jean-Jaques Muyembe

{"title":"MVA-BN monkeypox vaccine safety in a clinical trial in the Democratic Republic of the Congo.","authors":"Nsengi Ntamabyaliro, Tyler Bonnett, Gail Potter, Emily Yox, Laurens Liesenborghs, Olivier Tshiani Mbaya, Veronique Nussenblatt, Tarcisse Kapene Kilara, Aline Biongo Engo, Emmanuella Muhima, Percy Velela, Laetitia Itunime, Jean-Luc Biampata, Placide Mbala, Mariano Lusakibanza, Michael Kombozi Basika, Gaston Tona, Susan Vogel, H Clifford Lane, Lori E Dodd, Jean-Jaques Muyembe","doi":"10.1038/s41541-026-01490-0","DOIUrl":"10.1038/s41541-026-01490-0","url":null,"abstract":"The MVA-BN vaccine is considered safe and effective and has been widely deployed to prevent monkeypox. However, safety and tolerability data from endemic areas are limited. We performed a single-arm clinical trial of the safety of the MVA-BN vaccine among adults in the Democratic Republic of the Congo (ClinicalTrials.gov: NCT05734508; Registered 21 February 2023). Participants were personnel working on a monkeypox therapeutics trial (PALM-007) conducted in a high-risk, endemic setting for monkeypox. Participants received two doses of vaccine 28 days apart and were actively followed up to 28 days after each dose to assess the safety profile of MVA-BN. From March 2023 to June 2024, 500 participants were enrolled and received their first vaccine dose; 494 (99%) received the second dose and associated follow-up. There were no adverse events (AEs) of grade 3 or higher observed during the study. 175 participants (35%) reported at least one vaccination site AE, the most common of which was mild or moderate vaccination site pain (120/500 first dose recipients (24%); 48/494 second dose recipients (10%)). There was one recorded case of breakthrough monkeypox occurring approximately 3 months after the second dose. This observational study provides further evidence that the MVA-BN monkeypox vaccine is generally safe and well-tolerated. As previously reported, the most common AEs were mild or moderate injection site reactions.","PeriodicalId":19335,"journal":{"name":"NPJ Vaccines","volume":" ","pages":""},"PeriodicalIF":7.2,"publicationDate":"2026-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13500695/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148056015","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0